# EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
Canonical URL: https://biopharmsignal.com/news/EYPT/eyepoint-to-report-first-quarter-2026-financial-results-on-may-6-2026-09ed11b6
Ticker: EYPT
Company: EyePoint Pharmaceuticals
Source: EyePoint Pharmaceuticals
Published: 2026-04-29 11:00 EST
## Summary

EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative...

## Article Body
EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and highlight recent corporate developments.

To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/hjmg6gw2 . A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio . A webcast replay will also be available on the Company website at the conclusion of the call.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU ™ , is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E ™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data is expected for wet AMD beginning in mid-2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU ™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors:

Tanner Kaufman / Jenni Lu FTI Consulting Direct: 203-722-8743 / 667-321-6018 tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:

Green Room Communications Direct: 850-384-2833 EyePointMedia@grcomms.com
## Recent Company News
- 2026-07-16 11:00 EST — [EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-daeb0fac) — Source: EyePoint Pharmaceuticals
- 2026-07-13 11:00 EST — [EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer](https://biopharmsignal.com/news/EYPT/eyepoint-appoints-tarek-s-hassan-m-d-as-chief-strategic-science-officer-4900131f) — Source: EyePoint Pharmaceuticals
- 2026-06-16 11:00 EST — [EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-3aba909d) — Source: EyePoint Pharmaceuticals
- 2026-05-19 11:00 EST — [EyePoint Announces Participation at Upcoming Investor Conferences](https://biopharmsignal.com/news/EYPT/eyepoint-announces-participation-at-upcoming-investor-conferences-cef7e0be) — Source: EyePoint Pharmaceuticals
- 2026-05-18 11:00 EST — [EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/EYPT/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-147957c3) — Source: EyePoint Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)